72
Participants
Start Date
October 31, 2007
Primary Completion Date
August 31, 2011
Study Completion Date
August 31, 2011
CT-011
IV infusion of 1.5 mg/kg of CT-011 on Day 1(60 to 90 days post autologous PBSCT). Treatment was repeated every 42 days for a total of three courses with treatment visits on Days 1, 43, and 85.
The University of Pittsburgh Medical Center, Pittsburgh
University of North Carolina, Chapel Hill
Duke University Medical Center, Durham
Cancer Center of the Carolinas, Greenville
Emory University-Winship Cancer Institute, Atlanta
Northside Hospital, Atlanta
Sarah Cannon Research Institute, Nashville
Ohio State University, Colombus
Case Western Reserve University, Cleveland
Karmanos Cancer Institute, Detroit
Rush University Medical Center, Chicago
The University of Chicago, Chicago
Baylor Sammons Cancer Center, Dallas
M.D. Anderson Cancer Center, Houston
Scripps Cancer Center, San Diego
Rajiv Gandhi Cancer Institute and Research Centre, Delhi
Gujarat Cancer and Research Institute, Ahmedabad
Jaslok Hospital and Research Centre, Mumbai
Deenanath Mangeshkar Hospital and Research Centre, Pune
Moores UCSD Cancer Center, La Jolla
Northwestestern Memorial Hospital, Chicago
Dana-Farber Cancer Institute, Boston
University of Michigan, Ann Arbor
Temple University, Philadelphia
Rambam Medical Center, Haifa
Hadassah Medical Organization, Jerusalem
Chaim Sheba Medical Center, Tel Hashomaer, Ramat Gan
Lead Sponsor
CureTech Ltd
INDUSTRY